COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,686 Articles (22,913 medRxiv, 8,773 bioRxiv)

Most recent first Previous |  Page 2229: Articles 22281-22290  | Next

System Dynamics Model of Possible Covid-19 Trajectories Under Various Non-Pharmaceutical Intervention Options in Low Resource Setting.
Kivuti-Bitok, L. W., Momodu, A. S., Jebet, J. C., Kimemia, F., Gichuki, I., Ngune, I.
10.1101/2020.10.06.20204487 — Posted: 2020-10-08
Personal protective equipment for reducing the risk of COVID-19 infection among healthcare workers involved in emergency trauma surgery during the pandemic: a systematic review protocol
Griswold, D., Gempeler, A., Kolias, A., Hutchinson, P. J., Rubiano, A. M.
10.1101/2020.09.26.20201954 — Posted: 2020-10-08
Age- and Sex-Specific Modelling of the COVID-19 Epidemic
Doerre, A., Doblhammer, G.
10.1101/2020.10.06.20207951 — Posted: 2020-10-08
Umbilical cord blood derived microglia-like cells to model COVID-19 exposure
Perlis, R. H., Edlow, A. G., Sheridan, S. D., Thanos, J. M., De Guzman, R. M., McCrea, L. T., Horng, J. E., Fu, T., Sellgren, C. M.
10.1101/2020.10.07.329748 — Posted: 2020-10-07
NSP 11 of SARS-CoV-2 is an Intrinsically Disordered Protein
Gadhave, K., Kumar, P., Kumar, A., Bhardwaj, T., Garg, N., Giri, R.
10.1101/2020.10.07.330068 — Posted: 2020-10-07 Discussion: Onsite
Mass spectrometric based detection of protein nucleotidylation in the RNA polymerase of SARS-CoV-2
Sussman, M. R., Conti, B. J., Kirchdoerfer, R. N.
10.1101/2020.10.07.330324 — Posted: 2020-10-07
Making the invisible enemy visible
Croll, T., Diederichs, K., Fischer, F., Fyfe, C., Gao, Y., Horrell, S., Joseph, A. P., Kandler, L., Kippes, O., Kirsten, F., Müller, K., Nolte, K., Payne, A., Reeves, M. G., Richardson, J., Santoni, G., Stäb, S., Tronrud, D., Williams, C., Thorn, A.
10.1101/2020.10.07.307546 — Posted: 2020-10-07 Discussion: Onsite | Offsite
SARS-CoV-2 has observably higher propensity to accept uracil as nucleotide substitution: Prevalence of amino acid substitutions and their predicted functional implications in circulating SARS-CoV-2 in India up to July, 2020
Roy, S., Nath, H., Mallick, A., Biswas, S.
10.1101/2020.10.07.329771 — Posted: 2020-10-07 Discussion: Onsite
Extremely potent human monoclonal antibodies from convalescent Covid-19 patients
Andreano, E., Nicastri, E., Paciello, I., Pileri, P., Manganaro, N., Piccini, G., Manenti, A., Pantano, E., Kabanova, A., Troisi, M., Vacca, F., Cardamone, D., De Santi, C., Benincasa, L., Agrati, C., Capobianchi, M. R., Castilletti, C., Emiliozzi, A., Fabbiani, M., Montagnani, F., Depau, L., Brunetti, J., Bracci, L., Montomoli, E., Sala, C., Ippolito, G., Rappuoli, R.
10.1101/2020.10.07.328302 — Posted: 2020-10-07 Discussion: Offsite
Production of ORF8 protein from SARS-CoV-2 using an inducible virus-mediated expression-system in suspension-cultured tobacco BY-2 cells
Imamura, T., Isozumi, N., Higashimura, Y., Ohki, S., Mori, M.
10.1101/2020.10.07.325910 — Posted: 2020-10-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).